Posted by Michael Wonder on 26 Jul 2024
Checkpoint Therapeutics announces FDA acceptance of BLA resubmission of cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma
25 July 2024 - PDUFA goal date of 28 December 2024 set by FDA.
Checkpoint Therapeutics today announced that the US FDA has accepted for review Checkpoint’s resubmission of its biologics license application for cosibelimab, its anti-programmed death ligand-1 antibody, as a potential new treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
